Gilead Sciences Inc. and Merck & Co. Inc. have discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial, which assessed the combination of Trodelvy and Keytruda for treating metastatic non-small cell lung cancer with high PD-L1 expression. Despite showing a numerical improvement in progression-free survival, the results did not achieve statistical significance, and the likelihood of a meaningful overall survival benefit was deemed low. Safety profiles remained consistent with known data, with no new safety signals reported. In a separate development, the companies announced positive results from two Phase 3 trials for a once-weekly HIV treatment regimen combining islatravir and lenacapavir, which met its primary efficacy endpoint. This investigational regimen showed statistical non-inferiority compared to existing therapies, leading to plans for regulatory submissions. Full data from both studies will be presented at upcoming medical meetings.